📆 Today we honor those making #clinicaltrials possible - the clinical research teams, participants and their families, sponsors, and more, especially those advancing #genetherapy and #celltherapy. Participating in a trial often involves years of appointments, uncertainty, and hope. We are grateful to each individual who is able to move science forward, and for the families and teams who support them. On International #ClinicalTrialsDay, we are reminded of the researchers, advocates, and regulatory professionals working to expand access and improve treatment options for people affected by #rarediseases who may benefit from CGT. Learn more about clinical trials for gene therapy on our #PatientEducation website: https://lnkd.in/gZ-6VnEW
American Society of Gene & Cell Therapy
Non-profit Organizations
Waukesha, WI 33,229 followers
ASGCT is the primary membership organization for professionals working in gene and cell therapy.
About us
The American Society of Gene & Cell Therapy is the primary professional membership organization for gene and cell therapy. The Society's members are scientists, physicians, patient advocates, and other professionals. Our members work in a wide range of settings including universities, hospitals, government agencies, foundations, and biotechnology and pharmaceutical companies. The mission of ASGCT is to advance knowledge, awareness, and education leading to the discovery and clinical application of genetic and cellular therapies to alleviate human disease. ASGCT's strategic vision is to be a catalyst for bringing together scientists, physicians, patient advocates, and other stakeholders to transform the practice of medicine by incorporating the use of genetic and cellular therapies to control and cure human disease.
- Website
-
http://www.asgct.org
External link for American Society of Gene & Cell Therapy
- Industry
- Non-profit Organizations
- Company size
- 11-50 employees
- Headquarters
- Waukesha, WI
- Type
- Nonprofit
- Founded
- 1996
Locations
-
Primary
Get directions
20800 Swenson Dr.
Suite 300
Waukesha, WI 53186, US
Employees at American Society of Gene & Cell Therapy
Updates
-
As we reflect on last week’s Annual Meeting, we are inspired and proud that we continue to serve as a single place where the cell and gene therapy professional community can come together and advance the field. We are humbled to be included in this TIME.com feature discussing one of the transformational discoveries presented this year. Dr. Kiran Musunuru said it best: "I don't think I'm exaggerating when I say that this is the future of medicine. We are showing it’s possible to make a personalized gene-editing therapy for a single patient in real time, and hope it inspires others to do the same." https://lnkd.in/e3qQnUuJ
-
THANK YOU for making #ASGCT2025 a success! Access sessions on demand until July 18. We can't wait to see you May 12-16, 2026 in #Boston! #ASGCT2025 #CGT #ASGCTadvocacy
-
-
Saturday’s final sessions: advances in #AAV, #oncolyticviruses, and new cell sources for untreatable conditions. Thank you for an inspiring week! #ASGCT2025
-
-
Join us! Currently underway at #ASGCT2025: Our Outstanding New Investigator Symposium is taking place from 10:15 AM - 12:00 PM in Hall F. This General Session features presentations from: - Dr. Rebecca Ahrens-Nicklas (Children's Hospital of Philadelphia) on rare metabolic diseases - Dr. Eric Smith (Dana Farber Cancer Institute) on CAR T-Cell therapy advances - Dr. Xavier Anguela (Nava Therapeutics) on gene therapies for monogenic indications - Dr. Benjamin Deverman (Broad Institute) on AAV capsid engineering for CNS applications Session co-chairs Dr. Matthew Porteus (Stanford) and Jennifer Wellman (Lilly Gene Therapy) are guiding the discussion. #ASGCT2025
-
Wrapping up an incredible #ASGCT2025! Today is your final opportunity to explore the Exhibit Hall and Career Fair. Don't miss your chance to discover cutting-edge platforms, expand your professional network, and potentially find your next career opportunity in #CGT.
-
-
How is #FDA's START Pilot Program accelerating #CGT development? Join our symposium at #ASGCT2025 from 3:45-5:30 pm to hear directly from participating companies! @NeurogeneInc, @ModernaTx, and @MyrtelleInc share their experiences with this innovative initiative. #ASGCTadvocacy
-
Just presented at #ASGCT2025!
CHOP and Penn Medicine, University of Pennsylvania Health System have delivered the first-ever personalized gene editing therapy for a patient with CPS1 deficiency, marking a major milestone in the application of CRISPR-based treatments for rare metabolic diseases. This case highlights the future of precision medicine—custom therapies tailored to an individual’s unique genetic mutation. Learn more about KJ and the future of personalized medicine: http://ms.spr.ly/6046SZLAI.
-
HAPPENING NOW: George Stamatoyannopoulos Memorial Lecture Join us this morning (10:15 AM-12:00 PM, Hall F) for the prestigious George Stamatoyannopoulos Memorial Lecture, a session honoring scientific excellence and featuring presentations from leaders in #CGT research. The session begins shortly with the announcement of multiple prestigious ASGCT awards, including: Excellence in Research Awards Mentorship Award Mavis Agbandje-McKenna Scholarship Following these honors, Dr. Tippi MacKenzie (UCSF) will present groundbreaking research on prenatal therapeutic approaches for severe genetic disorders, highlighting innovative in utero intervention strategies. Dr. Kiran Musunuru (University of Pennsylvania) will then share advances in therapeutic gene editing for cardiovascular and metabolic conditions. The session concludes with the presentation of the Outstanding Achievement Award to Dr. Jeffrey Chamberlain (University of Washington) in recognition of his significant contributions to the field. Co-chaired by Drs. Paula Cannon and Terence Flotte, this memorial lecture serves as both a scientific forum and a tribute to Dr. Stamatoyannopoulos's pioneering contributions to gene therapy research. #ASGCT2025 #GeneticMedicine #ScientificExcellence
-
-
When #CGT programs face deprioritization, patients, researchers, and industry must collaborate on solutions. Join us for "Reviving Hope in Deprioritized CGT Programs" fireside chat at #ASGCT2025. This session will explore: • Intellectual property concerns • Funding challenges • Innovative pathways for revival • Perspectives Featuring Dr. Donald Kohn (UCLA), Rachel McMinn (Neurogene), and Oralea Marquardt (NTSAD). Wednesday, May 14, 3:45-5:30 pm at #ASGCT2025
-